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Background: Previous studies have demonstrated that chemokine CXCL12 and its receptor CXCR4 are critical for
pain sensitization, but the mechanisms involved are not clear. In this study, we investigated the specific cellular
mechanisms of CXCL12/CXCR4 chemokine signaling in the development and maintenance of bone cancer pain
after tumor cell implantation (TCI).
Methods: TCI in the tibial cavity of rats was used to establish a bone cancer pain model. Mechanical allodynia and
thermal hyperalgesia were determined by measuring the paw withdrawal threshold and latency, respectively. The
protein expression and cellular localization of CXCL12 and CXCR4 were detected by western blot and
immunofluorescence staining. The sensitization of neurons, activation of astrocytes and microglia were examined
by observing the immunofluorescence intensity of c-Fos, GFAP and IBA1.
Results: Our results demonstrated that CXCL12 was upregulated in a time-related manner, both in the dorsal root
ganglia and spinal cord after TCI. Spinal CXCL12 was predominately expressed in astrocytes, and an intrathecal
injection of astrocyte metabolic inhibitor fluorocitrate or selective JNK inhibitor SP600125 abolished TCI-induced
CXCL12 production. A single intrathecal injection of a CXCL12 neutralizing antibody (10 μg/10 μl) at day 10
after TCI transiently reversed bone cancer pain in a dose-dependent manner. Whereas repetitive intrathecal
administration of a CXCL12 neutralizing antibody (10 μg/10 μl, once a day from day 3 to 5 after TCI) significantly
delayed the onset of TCI-induced pain behaviors for nearly five days. Spinal CXCR4 was also upregulated after TCI
and colocalized with neurons, astrocytes and microglia. Blocking CXCR4 suppressed TCI-induced activation of
neurons, astrocytes and microglia in the spinal cord at day 14. Repeated intrathecal administration of AMD3100
(5 μg/10 μl, once a day for three days) significantly delayed and suppressed the initiation and persistence of bone
cancer pain in the early phase (at day 5, 6 and 7 after TCI) and in the late phase (at day 12, 13 and 14 after TCI) of
bone cancer, respectively.
Conclusions: Taken together, these results demonstrate that CXCL12/CXCR4 signaling contributed to the
development and maintenance of bone cancer pain via sensitizing neurons and activating astrocytes and microglia.
Additionally, this chemokine signaling may be a potential target for treating bone cancer pain.
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Bone cancer pain (BCP) is a common symptom among
patients with advanced breast, lung, and prostate cancer
as these tumors have a prominent affinity to metastasize
to the skeleton. In epidemiological studies, 75 to 90% of
patients with metastatic or advanced stage cancer will ex-
perience significant cancer-induced pain, which is disrup-
tive to their quality of life [1]. Unfortunately, persistent
pain is often difficult to effectively treat with conventional
drugs in bone cancer cases [2]. Although the general char-
acteristic of BCP is similar to inflammatory and/or neuro-
pathic pain in some states, the classical mechanism
underlying this chronic pain simply cannot explain the
BCP processing, which is triggered by inflammatory,
neuropathic and tumorigenic components simultaneously
[3-5]. Therefore, it is necessary to investigate the specific
molecular and cellular mechanisms by which the cancer
cells induce pain sensitization.
Although the origin of BCP is driven initially in the
bone microenvironment [6], the neuronal sensitization
and glial activation in the spinal cord (SC) level are more
far-reaching for contributing to pain hypersensitivity fol-
lowing bone cancer [7]. Accumulating evidence indicates
that astrocytes and microglia are activated in the spinal
cord dorsal horn (SCDH) after TCI [8] or nerve injury [9].
These activated glial cells are sufficient to trigger the per-
sistent pain hypersensitivity through forming an integrated
network of glial-neuronal and/or glial-glial interaction
[10]. In particular, the potent inflammatory mediators re-
leased from activated glial cells (such as chemokines) have
been demonstrated to mediate functional nerve cellular
communication, and thereby contribute to persistent pain
processing [11,12].
The chemokine CXC motif ligand 12 (CXCL12),
formerly named stromal cell-derived factor 1 (SDF-1), is
expressed in various kinds of cells in the central nervous
system (CNS) and plays an important role in neuro-
genesis, neuronal migration and neuronal differentiation
during the development of the nervous system. The che-
mokine CXC motif receptor 4 (CXCR4), which belongs to
seven-transmembrane-domain G-protein-coupled recep-
tors (GPCRs), is a major type of receptor for CXCL12.
CXCL12/CXCR4 chemokine signaling plays a critical role
in modulating various nervous system developmental
processes and in regulating synaptic plasticity [13]. Dys-
regulation of this signaling may be an etiological cause
for deficient CNS development, oncogenic processes
[14] and stroke [15]. Recently, this chemokine signaling
has attracted much attention because of its emerging
involvement in nociceptive signal regulation. Previous
studies have shown that intraplantar inoculation or intra-
thecal injection of exogenous CXCL12 into naïve rats
promote a sustained mechanical allodynia [16,17]. In cer-
tain pain-related models, the expression of CXCL12 and/or CXCR4 are significantly increased in the dorsal root
ganglion (DRG) or SC, and that blocking CXCR4 can
reverse pain-related behaviors [18-20]. Furthermore,
CXCL12/CXCR4 signaling has been shown to mediate
the induction of TNF-α, NF-κB and IL-6 release from
glial cells [21], which could lead to a further nociceptive
sensitization. However, it remains largely unknown whether
the CXCL12/CXCR4 signaling contributes to pain hyper-
sensitivity in a bone cancer state.
In this study, we set out to investigate whether
CXCL12 and CXCR4 are induced in SCDH and partici-
pate in BCP by using a rat tibia cancer pain model. We
provide the first evidence that the implantation of Walker
256 mammary gland carcinoma cells into a rat tibia pro-
duces increased expressions of CXCL12 and CXCR4 in
the SC, and that CXCL12/CXCR4 signaling-mediated
neuronal sensitization and glial activation are crucial for
the development and maintenance of BCP. Furthermore,
spinal CXCL12/CXCR4 signaling is now proven to be a
potential analgesic target for BCP management.
Methods
Animals
Adult female Sprague-Dawley (SD) rats (Experimental
Animal Center, Xuzhou Medical College, Xuzhou, China)
weighing 180 to 200 g were housed in plastic cages and
maintained on a 12:12 hour light/dark circle under condi-
tions of 24°C ± 1°C with food and water available. Before
the experiments manipulation, the animals were allowed
to habituate in the cages for at least three days. All experi-
mental protocols and animal-handling procedures were
performed according to protocols approved by the Animal
Care and Use Committee of Xuzhou Medical College, and
were consistent with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and
the International Association for the Study of Pain’s guide-
lines for pain research [22]. All efforts were made to
minimize the number of animals used and to minimize
their suffering.
Preparation of cells
Walker 256 mammary gland carcinoma cells (Institute
for Biomedical Research of Shanghai, Shanghai, China)
were derived from SD rats. Ascitic tumor cells (2 × 107
cells/ml, 0.5 ml) were injected into the abdominal cavity
of the SD rats weighing 60 to 80 g. After 6 to 7 days,
cancerous ascites was extracted in a sterile fashion, and
the tumor cells were subsequently washed with sterile
normal saline (NS) three times by centrifugation for five
minutes at 1000 rpm. The pellet was resuspended with
NS and adjusted to an appropriate concentration (1 × 105
cells/μl). The cell suspension was kept on ice until it was
injected into rats. For the sham-operated rats, equivolume
sterile NS was prepared for injection.
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As previously described [23,24], rats were anesthetized
with chloral hydrate (400 mg/kg, i.p.). The right leg of
each rat was shaved and a superficial incision was made
in the skin overlying the patella after disinfection with
75% (v/v) ethanol. Then a further incision was cut along
the patellar ligament to expose the tibial head with min-
imal damage. Prepared tumor cells (5 μl) were slowly
injected into the right tibia cavity of each rat using a 10 μl
microinjection syringe. The syringe was left in place for an
additional minute to prevent the tumor cells from leaking
out along the injection track. The injection site was closed
using bone wax after the syringe was removed to prevent
tumor cell overflow. Sham surgery was implemented using
a similar procedure by injecting sterile NS (5 μl).
Drugs and administration
The Jun N-terminal kinases (JNK) inhibitor SP600125
was purchased from Cell Signaling Technology (Danvers,
Massachusetts, United States). Anti-CXCL12 neutralizing
antibody and anti-IgG antibody (for control) were pur-
chased from Abcam (Cambridge, Massachusetts, United
States). Astrocytic inhibitor fluorocitrate and CXCR4 in-
hibitor AMD3100 were purchased from Sigma Aldrich (St
Louis, Missouri, United States). SP600125 were dissolved in
dimethyl sulfoxide (DMSO) and diluted in NS (final con-
centration of DMSO: 1%). Anti-CXCL12 neutralizing anti-
body and control IgG antibody were dissolved in a sterile
artificial cerebrospinal fluid (aCSF) containing 126.6 mM
NaCl, 2.5 mM KCl, 2.0 mM MgCl2, and 1.3 mM CaCl2.
Fluorocitrate and AMD3100 were dissolved in saline. The
volume for the intrathecal (i.t.) injection was 10 μl. All
doses of drugs were based on the results of preliminary ex-
periments. The dose of each drug and time points of treat-
ment were presented in the parts of figure legends.
The method described by Xu JJ et al. was used for the
intrathecal injection of drugs [25]. Briefly, the rats were
anesthetized with isoflurane. The lumbar region was disin-
fected with 75% (v/v) ethanol after hair shaving, and the
intervertebral spaces were widened by placing the animal
on a plexiglass tube. Next, a 29-gauge microinjection syr-
inge needle filled with the drug was inserted in the L5-6
interspace. The correct subarachnoid positioning of the
tip of the needle was verified by a tail- or paw-flick re-
sponse immediately after inserting the needle. Then the
injection needle was left in place for a further 15 seconds.
Motor function was evaluated by the observation of pla-
cing or stepping reflexes and righting reflexes at 2 minutes
before a nociceptive test. Animals with signs of motor dys-
function were excluded from the experiments.
Assessment of mechanical allodynia
Mechanical allodynia was determined by measuring the
paw withdrawal threshold (PWT) in response to VonFrey hair (Stoelting, Wood Dale, Illinois, United States)
stimulation. The protocol was similar to Dixon’s up and
down method described by Chaplan SR et al. [26]. In
briefrats wereindividually placed in a plastic cage with a
plexiglass floor and allowed to acclimate for 1 hour
before testing. An ascending series of Von Frey hairs
(0.4, 0.6, 1.4, 2, 4, 6, 8 and 15 g) were applied to the
mid-plantar surface of each hind paw. Each Von Frey
hair was held for 5 to 6 seconds with a 5-minute interval
between applications. The trial began with the applica-
tion of the 2 g Von Frey hair. A positive response was
defined as brisk withdrawal or paw flinching upon stimu-
lus. Whenever a positive response to a stimulus occurred,
the next lower Von Frey hair was applied, and whenever a
negative response occurred, the next higher hair was ap-
plied. The testing consisted of five more stimuli after the
first change in response occurred, and the data were
analyzed using the up and down method. The behavioral
testing was performed by an investigator blinded to the
treatment.
Assessment of thermal hyperalgesia
Thermal hyperalgesia was determined by measuring the
paw withdrawal latency (PWL) in response to radiant heat
stimulation. A Plantar Analgesia Meter (IITC Life Science
Inc., Victory Blvd Woodland Hills, California, United
States) was used to provide a heat source. The protocol
was similar to that described by Hargreaves et al. [27]. In
brief, each rat was placed in a plastic chamber containing
a clear glass floor and allowed to acclimatize to the envir-
onment for one hour. The radiant heat source was deliv-
ered and focused onto the glabrous surface of the paw
through the glass floor. An automatic 20 second cutoff
was used to prevent tissue damage. Thermal stimulus
were delivered three times to each hind paw at 5-minute
intervals. The intensity of the heat stimulus was main-
tained constantly throughout this study.
Immunohistochemistry
Under deep anesthesia, rats were intracardially perfused
with phosphate-buffered saline (PBS) followed by 4% para-
formaldehyde (PFA). Then the L4-5 spinal cord segment
was dissected and post-fixed in 4% PFA for 3 hours, and
subsequently allowed to equilibrate in 30% sucrose in a
phosphate buffer (PB) overnight at 4°C. The embedded
blocks were sectioned 30 μm thick in a cryostat and stored
in PBS for immunofluorescence. The sections were first
blocked with 5% donkey serum and 0.3% Triton X-100 for
1hour at room temperature, then incubated overnight at
4°C with the following primary antibodies: rabbit anti-
CXCL12 polyclonal antibody (1:100, sc-28876, Santa Cruz
Biotechnology, Santa Cruz, California, United States),
rabbit anti-CXCR4 polyclonal antibody (1:200, ab2074,
Abcam, Cambridge, Massachusetts, United States), mouse
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Conjugate, MAB377X, Millipore, Billerica, Massachusetts,
United States), mouse anti-GFAP monoclonal antibody
(1:400, Alexa Fluor 488 Conjugate, #3655, Cell Signaling
Technology, Beverly, Massachusetts, United States), goat
anti-IBA1 polyclonal antibody (1:400, ab5076, Abcam,
Cambridge, Massachusetts, United States ), rabbit anti-
c-Fos polyclonal antibody (1:800, ab7963, Abcam, Cambridge,
Massachusetts, United States ). The sections were then
washed 3 times with PBS and incubated with the specific
secondary antibodies raised in donkey serum(conjugated
to Alexa Fluor 488 or 594, Invitrogen, Carlsbad, California,
United States) overnight at 4°C. For double staining,
sections were incubated again in the same blocking so-
lution and the staining process was performed once
again. After immunostaining procedures, the sections were
examined using a laser scanning confocal microscopy
(FV1000, Olympus, Tokyo, Japan).
According to the previous description [28,29], c-Fos
immunoreactive neurons were counted in a blind fash-
ion. The number of c-Fos like immunoreactive neurons
in the dorsal horn of the spinal cord (laminae I-VII) was
determined by averaging the counts made in 30 spinal
cord sections for each group (n = 5). To obtain quantita-
tive measurements of GFAP and IBA1 immunofluores-
cence in the dorsal horn, 15 to 20 fields covering the
entire dorsal horn in each group (n = 5) were evaluated
and photographed at the same exposure time to generate
the raw data. The average green fluorescence intensity of
each pixel was normalized to the background intensity
in the same image.
Western blot analysis
The L4-5 spinal cords and DRGs were quickly extracted
from deeply anesthetized rats, then the tissue samples
were dissected and stored in liquid nitrogen. The tissues
were homogenized in a lysis buffer (Bio-Rad Laboratories,
Hercules, California, United States) containing a cocktail
of protease inhibitor and phosphatase inhibitors (Sigma
Aldrich, St Louis, United States). Then homogenates were
centrifuged at 12000 g for 15 minutes at 4°C. The super-
natants of the homogenates were collected and the pro-
tein concentration of the supernatants was estimated
using the method of bicinchoninic acid assay. The total
protein content among samples was equalized. The sam-
ples were dissociated by heating at 100°C for five minutes
in a loading buffer (2% sodium dodecyl sulfate, 100 mM
dithiothreitol, 10% glycerol, and 0.02% bromophenol blue).
Then equivalent amounts of protein (80 μg) were sepa-
rated using 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred onto
a polyvinylidene fluoride membrane (PVDF, Millipore,
Billerica, Massachusetts, United States). The membranes
were placed in a blocking solution, which contained Tris-buffered saline with 0.02% Tween (TBST) and 5% non-fat
dry milk, for two hours at room temperature, and then
incubated overnight at 4°C with rabbit anti-CXCL12
polyclonal antibody (1:400, sc-28876, Santa Cruz Biotech-
nology, California, United States), rabbit anti-CXCR4
polyclonal antibody (1:1000, ab2074, Abcam, Cambridge,
Massachusetts, United States) and glyceraldehyde-3-phos
phate dehydrogenase (GAPDH, 1:50000, G9545, Sigma, St
Louis, Missouri, United States) , respectively.
Data were analyzed with Quantity One Analysis Soft-
ware (Version 4.6.5, Bio-Rad Laboratories, Hercules,
California, United States). Each of the groups was first
standardized with the control GAPDH. The mean value
of the sham group (n = 5) was set as 1, which was used
for normalization for each of the 5 sham groups. For
each of the molecules detected (n = 5), the sham group
(set as 1) was used for normalization of the protein ex-
pression in the TCI groups at every data points after
different treatments. The results were showed in the fig-
ures as fold changes.
Statistical analyses
GraphPad Prism 5 (GraphPad Software, La Jolla, California,
United States) was used to conduct all statistical analyses.
Alterations of detected protein expression and changes
of behavioral responses to mechanical and thermal stimuli
over time among groups were tested using one-way ana-
lysis of variance (ANOVA) with repeated measures,
followed by the Dunnett multiple comparison test, and
two-way ANOVA with repeated measures, followed by
Bonferroni post hoc test, respectively. All data are pre-
sented as means ± SEM. Statistical results are consid-
ered significant if P < 0.05.
Results
Spinal CXCL12 is upregulated in astrocytes after TCI
Bone cancer-induced chemokine changes in the SC are
critical for BCP generation [30-33]. Here we examined
whether CXCL12/CXCR4 chemokine signaling could be
functional upregulated in BCP state. We first detected
the expression and distribution of CXCL12 in the SC
after TCI. Our western blot analysis showed that TCI in-
duces a rapid-onset and long-lasting increased expres-
sion of CXCL12 protein from day 3 to day 21 after TCI.
The increase evidently began at day 3, peaked at day 7
to 10, and remained at high level until day 21, the last
test day (Figure 1A). However, CXCL12 protein was at a
low level in the SC of sham-operated rats. In addition,
the immunoreactivity of CXCL12 at the start was dis-
tributed predominantly in the superficial layers (laminae
I-II) at day 3 and 5 after TCI. However, CXCL12 was
not restricted to the superficial dorsal horn (DH) for the
whole time. A widespread induction of CXCL12 was ob-
served in SCDH at day 10 and 14 after TCI (Figure 1B).
Figure 1 Expression and distribution of CXCL12 protein in the spinal cord after TCI in rats. (A) Western blot analysis shows time course of
CXCL12 expression in sham and TCI rats. Five spinal cord segments were included in each group. Representative bands are shown on the top;
data summary is shown on the bottom. *P < 0.05, **P < 0.01 versus sham control. (B) Immunofluorescence shows expression of CXCL12 protein
(green) in rat spinal cord at different time points. Tissues were collected at day 3, 5, 10, 14 after TCI. Original magnification: 200× for all the
confocal images showing the dorsal horn ipsilateral to TCI (bar = 100 μm).
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following TCI treatment, we performed double immu-
nostaining of CXCL12 with three major spinal nerve
cell-specific markers: NeuN (for neurons), GFAP (for
astrocytes), and IBA1 (for microglia). Confocal images
showed that GFAP and IBA1 were expressed at a low
immunoreactivity in SCDH of sham-operated rats, but
were increased at day 10 after TCI, indicating the activa-
tion of astrocytes and microglia was caused by TCI. Fur-
thermore, the double immunostaining of CXCL12 wasFigure 2 Cellular localization of CXCL12 expression in spinal cord dor
(red) is colocalized with GFAP (green, middle), a marker for astrocytes, but
a marker for microglia. Tissues were collected 10 days after TCI. Two single
confocal images showing the dorsal horn ipsilateral to TCI (bar = 50 μm).extensively colocalized with GFAP, but hardly coloca-
lized with NeuN or IBA1, suggesting that CXCL12 is
induced by astrocytes, but not neurons or microglia in
BCP rats (Figure 2). These results demonstrate that
spinal CXCL12 is upregulated after TCI, and predomin-
ately expressed in activated astrocytes.
CXCL12 is also increased in DRG after TCI
To investigate whether, besides spinal astrocytes, DRG
would be another source for the spinal CXCL12sal horn of sham and TCI rats. Double staining shows that CXCL12
not with NeuN (green, left), a marker for neurons or IBA1 (green, right),
-stained images were merged. Original magnification: 400× for all the
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pression in DRG level. Our western blot analysis showed
that TCI induces a rapid-onset but short-duration upregu-
lation of DRG CXCL12 expression after TCI. The CXCL12
evidently increased on day 3 and day 5, then rapidly de-
creased to a normal level from day 7 to day 21 (Figure 3A).
This data suggested that the increased CXCL12 in the
spinal cord at the early phase may be coming from DRG
through axonal transportation. However, neither spinal nor
DRG CXCL12 expression was statistically increased at day
1 after TCI (Figure 3B).TCI induces CXCL12 upregulation in spinal astrocytes via
JNK pathway
To examine whether the production of CXCL12 is re-
quired for the activation of astrocytes, we intrathecally
injected an astrocyte metabolic inhibitor fluorocitrate [34]
(1 nmol/10 μl) into the bone cancer rats once daily for
three consecutive days (from day 8 to 10 after TCI), then
detected the GFAP immunoreactivity and CXCL12 pro-
tein level after the last injection. Compared with sham-
operated rats, the immunofluorescence intensity of GFAP
and expression level of CXCL12 were increased at day 10
in TCI-treated rats. After repeated fluorocitrate adminis-
tration, however, the TCI-induced GFAP immunofluo-
rescence expression was abolished (Figure 4A and B).
Further more, the TCI-induced CXCL12 protein upregula-
tion was also inhibited when associated with GFAP de-
crease (Figure 4C). In contrast, saline did not affect GFAP
immunofluorescence intensity or CXCL12 protein expres-
sion in BCP rats.
The JNK is known to activate in spinal astrocytes after
nerve injury [35] or bone cancer [36], and JNK activation
appears to regulate the production of certain chemokinesFigure 3 Expression of CXCL12 protein in DRG after TCI in rats. (A) W
sham and TCI rats. (B) Western blot analysis shows DRG or SC CXCL12 exp
each group. Representative bands are shown on the top; data summary isin astrocytes [37,38]. To further define whether JNK is the
upstream of CXCL12 after TCI, we blocked the JNK path-
way with the selective JNK inhibitor SP600125 [37] (20
nmol/10 μl, i.t. once daily from day 8 to 10 after TCI) and
then detected CXCL12 protein level after the last injection.
Compared with the control DMSO, SP600125 reversed
TCI-induced CXCL12 increase after three consecutive days
of i.t. administration (Figure 4D). Collectively, these find-
ings suggest that JNK pathway mediates TCI-induced pro-
duction of spinal CXCL12 in activated astrocytes.CXCL12 neutralizing antibody attenuates mechanical
allodynia and thermal hyperalgesia caused by TCI
To elucidate whether suppressing spinal CXCL12 could
inhibit pain-related behaviors following TCI, we intra-
thecally injected a CXCL12 neutralizing antibody [39]
into sham and TCI-operated rats. We first tested the an-
algesic effect of acute CXCL12 inhibition by a single i.t.
injection of CXCL12 neutralizing antibody at day 10 after
TCI. At this time point, the pain-related behaviors are
well-established and the upregulation of CXCL12 remains
at a high level. The TCI significantly decreased PWT and
PWL in the ipsilateral side at day 10. Compared with con-
trol IgG (10 μg/10 μl) treatment, BCP rats treated with
CXCL12 neutralizing antibody, at the dose of 10 μg (but
not 1 μg), showed a transient recovery in the decreased
levels of mechanical threshold and thermal latency at 2, 4,
8, 16 hours after antibody administration (Figure 5A and
B). These results indicate that CXCL12 may be involved
in the maintenance of BCP.
Considering the upregulated expression of spinal CX-
CL12 began at day 3, about two days prior to the
detectable onset of cancer pain-related behaviors, we
hypothesized that TCI-induced rapid-onset increase ofestern blot analysis shows time course of DRG CXCL12 expression in
ression in sham and TCI rats at day 1. Five samples were included in
shown on the bottom. **P < 0.01 versus sham control.
Figure 4 Intrathecal administration of fluorocitrate or SP600125 reverses TCI-induced upregulation of CXCL12 protein in the spinal cord.
(A) Confocal images show inhibitory effect of fluorocitrate on induction of astrocytic marker GFAP (green) after TCI. Original magnification: ×200.
(B) Mean green immunofluorescence intensity of GFAP of A among sham, TCI and TCI + Fluorocitrate group. For control experiments, saline was used.
Fluorocitrate (1 nmol/10 μl, i.t.) or saline (10 μl, i.t.) was given once a day on postoperative days 8, 9 and 10, respectively. Tissues were collected 4 hours
after the last spinal injection (n = 5 in each group). *P < 0.05, **P < 0.01 versus sham + saline. ##P < 0.01 versus TCI + saline. (C) Western blot and data
summary show inhibitory effect of fluorocitrate on TCI-induced increased expression of CXCL12 protein (n = 4 in each group). (D) Western blot and
data summary show inhibitory effect of SP600125 on TCI-induced increased expression of CXCL12 protein (n = 4 in each group). SP600125 (20 nmol/
10 μl, i.t.) or DMSO (for control, 10 μl, i.t.) was given once a day on postoperative days 8, 9 and 10, respectively. Tissues were collected 6 hours after the
last spinal injection. **P < 0.01 versus sham+DMSO. ##P < 0.01 versus TCI + DMSO.
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BCP. In support of our hypothesis, we further investi-
gated the analgesic effect of CXCL12 neutralizing anti-
body on pain behavior induction. The behavioral data
showed that repeated treatment of CXCL12 neutralizing
antibody (10 μg i.t., once a day from day 3 to 5 after
TCI) for three continuous days significantly delayed the
onset of mechanical allodynia and thermal hyperalgesia
for almost five days (Figure 5C and D). To test the effect
of control IgG and CXCL12 neutralizing antibody on basal
nociceptive condition, we i.t. injected IgG or CXCL12
neutralizing antibody (10 μg/10 μl) in sham rats, and then
tested the PWT and PWL. The behavioral results showed
that neither control IgG nor CXCL12 neutralizing anti-
body affect the PWT or PWL from day 3 to 14 after TCI.
Taken together, these behavioral results provide strong
evidence that CXCL12 in the spinal cord is critical for
TCI-induced pain sensitization.
Expression and distribution of CXCR4 in spinal cord
after TCI
CXCR4 is a major type of receptor for CXCL12. We fur-
ther investigated whether the spinal CXCR4 could be
triggered after CXCL12 upregulation in BCP condition.Compared with the rapid-onset of CXCL12, the increased
expression of its receptor CXCR4 delayed by two days,
then peaked at day 7 to day 10, and remained at a high
level until day 21. Whereas, the expression of CXCR4
protein was also at a low level in sham rats (Figure 6A).
Additionally, our immunofluorescence result showed that
CXCR4 predominantly distributed in the superficial layers
at day 3 and 5 after TCI. However, this is followed by a
widespread induction of CXCR4 both in the surface and
deeper layers at day 10 and 14 after TCI (Figure 6B).
Given that the localization of CXCR4 determines the
functional targets of CXCL12/CXCR4 signaling, we then
examined the cellular distribution of CXCR4 with NeuN,
GFAP and IBA1 in SCDH of TCI or sham rats. Confocal
images showed that after TCI treatment immunoreactiv-
ity of CXCR4 was predominantly colocalized with neu-
rons and astrocytes, and a small amount with microglia.
However, the immunoreactivity of CXCR4, GFAP and
IBA1 in the sham rats was quite weak (Figure 7).
Blocking CXCR4 suppresses TCI-induced activation of
neurons and glial cells
TCI causes neurochemical alterations such as c-Fos,
GFAP and IBA1 in the ipsilateral DH, in addition to
Figure 5 Effects of CXCL12 neutralizing antibody in spinal cord on mechanical and thermal hypersensitivity induced by TCI. (A, B)
Intrathecal injection of CXCL12 neutralizing antibody (10 μg, but not 1 μg) partially and transiently reverses TCI-induced mechanical allodynia
(A) and thermal hyperalgesia (B) in the feet ipsilateral to TCI. Pain behaviors were measured on postoperative day 10. #P < 0.05, ##P < 0.01 versus
TCI + control IgG. (C, D) Intraspinal injection of CXCL12 neutralizing antibody (10 μg/10 μl, once a day for three consecutive days on days 3, 4,
and 5 after TCI) delays TCI-induced induction of mechanical allodynia (C) and heat hyperalgesia (D). **P < 0.01 versus sham + control IgG.
#P < 0.05, ##P < 0.01 versus TCI + control IgG. TCI was performed on day 0. The dose of control IgG was 10 μg/10 μl. Each administration is
indicated by an arrow on the corresponding time point. Ten rats were included in each group.
Figure 6 Expression and distribution of CXCR4 protein in spinal cord after TCI in rats. (A) Western blot analysis shows time course of
CXCR4 expression in sham and TCI rats. Five spinal cord segments were included in each group. Representative bands are shown on the top;
data summary is shown on the bottom. **P < 0.01 indicate significant differences compared with group of sham control. (B) Immunofluorescence
shows expression of CXCR4 protein (green) in rat spinal cord at different time points. Tissues were collected at day 3, 5, 10 and 14 after TCI.
Original magnification: 200× for all the confocal images showing the dorsal horn ipsilateral to TCI (bar = 100 μm).
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Figure 7 Cellular localization of CXCR4 expression in spinal cord dorsal horn of sham and TCI rats. Double staining shows that CXCR4
protein (red) is co-expressed with neuronal marker NeuN (green, left), astrocytic marker GFAP (green, middle), and microglial marker IBA1 (green,
right). Tissues were collected 10 days after TCI. Original magnification: 400× for all the confocal images showing the dorsal horn ipsilateral to TCI
(bar = 50 μm).
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cellular consequences after CXCR4 upregulation, we con-
tinued to investigate whether CXCR4 would be involved
in the activation of neurons (c-Fos), astrocytes (GFAP)
and microglia (IBA1) caused by TCI. Our immunofluores-
cence images showed that TCI-induced induction of c-Fos
and activation of GFAP and IBA1 were all greatly sup-
pressed by AMD3100 (5 μg/10 μl, i.t., once a day from day
12 to 14 after TCI) for three consecutive days. The results
indicate that spinal CXCR4 may directly mediate the
sensitization of neurons and activation of astrocytes and
microglia in the BCP condition (Figure 8).
AMD3100 prevents and alleviates bone cancer pain in the
early- and late-phase
Previous reports have shown that systematic administra-
tion of AMD3100 attenuates the pain hypersensitivity in
some rat models of neuropathy [18-20]. Here, we first re-
ported the analgesic effects of AMD3100 on bone cancer-
induced pain in TCI-operated rats. As the capability of
AMD3100 on crossing the blood–brain barrier is not
clear, we employed the method of intrathecal injection to
observe the direct effects of this drug at the spinal level.
The drug dosage was determined by preliminary experi-
ments. Repetitive i.t. administration of AMD3100 (5 μg/
15 μl, once a day for three days) significantly delayed the
initiation of mechanical allodynia and thermal hyperalge-
sia for three days at the early phase (day 5, 6 and 7 after
TCI) of bone cancer (Figure 9A and B). Furthermore,
established mechanical allodynia and thermal hyperalgesia
were also significantly reversed by repetitive i.t. adminis-
tration of the same dose of AMD3100 at the late phase(day 12, 13 and 14 after TCI) of bone cancer (Figure 9C
and D). While normal pain sensation in the sham rats was
not altered by AMD3100 or saline, these results indicate
that CXCL12/CXCR4 signaling indeed plays an important
role in the production and persistence of BCP.
Discussion
Neuronal sensitization associated with glial activation in
SC has been shown to be important in the development
and maintenance of pain hypersensitivity in bone cancer
state. There is growing evidence that chemokines (such as
CCL2, CCL5, CXCL1 and CX3CL1) are involved in neur-
onal sensitization and/or glial activation in SC [11,38,41],
and some of them contribute to BCP processing [30,42].
In this study, we characterized the expression, distribution
and function of chemokine CXCL12 and its receptor
CXCR4 in TCI model of BCP. The principal findings of
our study are: (1) TCI induced a rapid-onset and long-
lasting upregulation of CXCL12 in SC, which is dependent
on astrocytes activation and JNK pathway. (2) A single i.
t. injection of CXCL12 neutralizing antibody transiently
reversed established-pain hypersensitivity induced by
TCI. Additionally, repetitive i.t. injection of CXCL12 neu-
tralizing antibody persistently delayed the induction of
TCI-induced pain hypersensitivity. (3) TCI also induced
upregulation of CXCR4 protein in SC, which is expressed
in neurons, astrocytes and microglia. (4) Repeated i.t. ad-
ministration of AMD3100, a selective CXCR4 inhibitor,
suppressed TCI-induced activation of neurons, astrocytes
and microglia in SCDH. (5) AMD3100 prevented and alle-
viated pain hypersensitivity following TCI in early and
later phase of bone cancer. These findings suggest that
Figure 8 AMD3100 suppresses TCI-induced upregulation of c-Fos, GFAP and IBA1 in spinal cord dorsal horn. (A) Confocal images shows
activation of neurons (c-Fos), astrocytes (GFAP) and microglia (IBA1) are suppressed by intraspinal injection of AMD3100. Original magnification:
200× for all the confocal images showing the dorsal horn ipsilateral to TCI (bar = 100 μm). (B) Data summary of A. AMD3100 (5 μg/10 μl, i.t.) was
given once a day on postoperative days 12, 13 and 14, respectively. Tissues were collected 6 hours after the last injection (30 spinal cord sections
in each group). *P < 0.05, **P < 0.01 versus sham; ##P < 0.01 versus TCI.
Figure 9 Intrathecal administration of AMD3100 prevents and attenuates bone cancer pain after TCI in rats. (A, B) Intrathecal
administration of AMD3100 (5 μg/10 μl, i.t., once a day) in the early phase (postoperative days 5, 6 and 7) delayed the onset of mechanical
allodynia (A) and thermal hyperalgesia (B) in TCI rats. (C, D) In the later phase (postoperative days 12, 13 and 14), AMD3100 (5 μg/10 μl, i.t., once
a day) suppressed the ongoing mechanical allodynia (C) and thermal hyperalgesia (D). TCI was done on day 0. Each administration is indicated
by an arrow on the corresponding time point. Ten rats were included in each group. *P < 0.05, **P < 0.01 versus sham + saline. #P < 0.05,
##P < 0.01 versus TCI + saline.
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in the development and maintenance of BCP.
To date, a growing body of evidence in rat experi-
ments shows that CXCL12 is expressed at key locations
of the pain transmission pathway in pathological pain
states. In the DRG level, nucleoside reverse transcriptase
inhibitors and prolonged morphine administration both
resulted in increased mechanical allodynia and CXCL12
mRNA upregulation [18,20]. In addition, CXCL12 mRNA
in the satellite glial cells was induced for 14 days following
chronic constriction injury [19]. In the SC level, CXCL12
immunoreactivity was also induced after spinal cord in-
jury, and co-expressed with pain-related peptides: sub-
stance P and calcitonin gene-related peptide (CGRP) [43].
By contrast, our results from western blot detection
showed that TCI induced a rapid (3 days) and persistent
(21 days) increase of CXCL12 protein in the SC. Further-
more, it was previously reported in an in vitro study that
CXCL12 is expressed intensely in astrocytes and weakly
in neurons, but not in microglia [44]. In our in vivo
study, immunofluorescence double staining detection
also showed that after TCI CXCL12 was increased and
predominantly expressed in astrocytes, but only occa-
sionally in neurons or microglia.
Astrocytes activation, referred to GFAP upregulation
and hypertrophy, was detected in various pathological
pain conditions, and was generally considered to be re-
sponsible for enhancing persistent pain states [34]. In the
CNS, astrocytes have been identified as sources of algo-
genic substance, because accumulating evidence indicates
that activated astrocytes can release pro-inflammatory cy-
tokines (such as IL-1β and TNF-α) and chemokines (such
as CCL2 and CXCL1) in the SC to enhance and prolong
pain processing [38,45-47]. We showed that fluorocitrate,
which disrupts astrocytes function, exerted a profound
blockade of CXCL12 induction in bone cancer states.
These data indicate that chemokine CXCL12 was also re-
leased from activated astrocytes. Furthermore, JNK, one
of the members of MAPK, is highly expressed in activated
astrocytes and regulates the production and release of
various chemokines (such as CCL2 and CXCL1) in neuro-
pathic pain conditions. In this study, we further found that
JNK inhibitor SP600125 reduced TCI-induced CXCL12
production, indicating that JNK is a critical upstream trig-
ger for CXCL12 upregulation in astrocytes after TCI.
Interestingly, our results showed that CXCL12 induc-
tion started detectable from day 3 after TCI. However,
GFAP was not activated until day 7 [48], suggesting that
CXCL12 may be also produced and released from other
cells in the early phase of bone cancer. Indeed, in a basal
condition CXCL12 was predominantly distributed in both
peptidergic CGRP and the non-peptidergic isolectin B4
(IB4) nociceptive neurons of DRG, and also found in
CGRP nociceptive terminals within DH, demonstratingthat CXCL12 was broadly expressed in the nociceptive
pathways. Therefore, we thought it necessary to detect the
CXCL12 expression in DRG level after TCI, in order to
explain the increase of CXCL12 in SC before astrocytes
activation. Our western blot analysis showed that TCI in-
duces a rapid-onset but short-duration upregulation of
CXCL12 expression in the DRG level at early phase. In
addition, our confocal images also showed that, at the very
start after TCI, spinal CXCL12 was distributed predomin-
antly in the superficial layers, which is the important re-
gion for processing nociceptive information from DRG to
SC. As time goes on, however, a widespread induction of
CXCL12 was observed in the whole SCDH after astrocytes
were activated. We thus hypothesized that, in bone cancer
state (especially in the early phase), CXCL12 is produced
in DRG nociceptive neurons that innervate the tumor-
bearing limb, and in turn axonally transported to the
surface layers of SCDH where it may be released locally.
While, in the later phase, CXCL12 is mainly produced
and released by spinal astrocytes, considering that, at
this time, DRG CXCL12 has been decreased to a normal
level and spinal astrocytes have been activated and dis-
tributed widely.
It is becoming clear that CXCL12 is produced from acti-
vated astrocytes via JNK pathway on bone cancer status.
However, whether CXCL12 contributes to bone cancer
pain depends on behavioral examination. In support of
this notion, we demonstrated for the first time, to our
knowledge, that the CXCL12 neutralizing antibody can
alleviate established cancer pain hypersensitivity by i.t. ad-
ministration, despite that the effect of anti-hyperalgesia
and anti-allodynia is transient. Certainly, our western blot
result showed that CXCL12 upregulation started from day
3 after TCI, while the cancer pain hypersensitivity was un-
detectable until day 5, suggesting that spinal CXCL12 may
be a trigger mediator for development of BCP. As ex-
pected, we further found that prolonged treatment of
CXCL12 neutralizing antibody in the early phase of bone
cancer markedly delayed the onset of BCP behavior. Thus,
our data supports a potential role of CXCL12 in the devel-
opment of BCP processing.
All chemokines exert their biological functions via ac-
tivating their surface receptors which are on different
types of cells. Annabelle et al. have reported that exogen-
ous CXCL12 directly induced mechanical hypersensitivity
in naïve rats through the stimulation of CXCR4 in the SC
[16]. Consistently, CXCR4 receptors have been observed
both in DRG and SC, and implicated in CXCL12-mediated
pain regulation after neuropathy. Remarkably, we found
that CXCR4 was significantly and persistently upregulated
accompanying CXCL12 production in SC after TCI. It is
becoming clear that, through releasing several chemokines,
the activated glial cells not only enhance neuronal
sensitization, but also further facilitate glial activation, and
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feedback loops, which are consist of glial-neuronal and
glial-glial communication, depend on both perseverant re-
lease of chemokines from glial cells and persistent activa-
tion of chemokine receptors on neurons and glial cells
[49]. In the present study, after confirming the origin of
CXCL12, we further observed that the increased CXCR4
was widely distributed around the neurons, astrocytes
and microglia as well, which is in parallel with previous
studies in pathological conditions. This find indicated
that CXCL12/CXCR4 signaling may be making major
contributions to nociceptive signal processing by medi-
ating glial-neuronal and glial-glial communication on
bone cancer state. Given the spinal blockade of CXCR4
inhibits TCI-induced induction of c-Fos and activation
of GFAP and IBA1 in SCDH, we further confirmed that
CXCL12/CXCR4 signaling contributes to a positive feed-
back loop of glial-neuronal/glial communication through
directly activating neurons and glial cells after TCI, which
are essential to BCP regulation. In addition, CXCR4
receptors activate various signaling pathways, such as
the mitogen-activated protein kinase (MAPK) pathway,
phospholipase C (PLC) pathway, and phosphatidyl inositol-
3 kinase (PI3K) pathway, which leads to varied functional
outcomes, including adhesion, polarization, and chemotaxis
[50,51]. These intracellular signaling pathways are also
involved in nociceptive regulation [52-54]. However,
whether CXCL12/CXCR4 signaling mediates BCP pro-
cessing through MAPK and/or PLC and/or PI3K path-
way in spinal glia needs to be investigated in the future.
As a specific antagonist of chemokine receptor CXCR4,
AMD3100 has been approved in human clinical trials for
hematopoietic stem cell mobilization to the peripheral
blood in patients with non-Hodgkin’s lymphoma and mul-
tiple myeloma [55,56]. It has also been demonstrated in
animal models that AMD3100 as a novel therapeutic con-
cept has been applied, particularly for the treatment of
tumor progression including angiogenesis, metastasis,
survival and bone destruction [57-59]. Our behavioral
results further demonstrated that spinal administration
of AMD3100 attenuated TCI-induced pain hypersensi-
tivity at the early induction phase and late maintenance
phase, suggesting the analgesic effect of AMD3100 on
BCP. If AMD3100 can block tumor growth, tumor-
induced bone destruction and BCP without substantial
side effects, treatment with AMD3100 may considerably
enhance the quality of life for patients with primary or
metastatic bone cancer.
Conclusions
In conclusion, our present study suggests that implant-
ation of Walker 256 mammary gland carcinoma cells
into the tibia of rats produces a prominent expression of
CXCL12/CXCR4 in the spinal cord, which may underliethe activation of these spinal neurons and glial cells as well
as hyperalgesic behaviors in bone cancer rats. Thus, the
blockade of this chemokine signaling in the spinal cord
may play a vital role in bone cancer pain management.
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